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Abstract
Background: Metastasis-associated in colon cancer-1 (MACC1) is a newly identified gene that plays a role in colon
cancer metastasis through upregulation of c-MET proto-oncogene (c-MET). However, the value of MACC1 as a
potential biomarker for hepatocellular carcinoma (HCC) remains unknown.
Methods: MACC1 mRNA expression in 128 HCC tissues was examined by quantitative polymerase chain reaction.
To show the potential correlation of MACC1 and c-MET, c-MET was also analysed.
Results: MACC1 was more highly expressed in HCC than in non-HCC tissues (P = 0.009). High MACC1 expression
was significantly increased in cases with high alpha fetoprotein (AFP) (P = 0.025). A positive correlation was found
between MACC1 and c-MET mRNAs (r = 0.235, P = 0.009). Both univariate and multivariate analyses revealed that
MACC1 expression was associated with overall survival (OS) and disease-free survival (DFS). Moreover, stratified
analysis showed that tumour-node-metastasis (TNM) stage I patients with high MACC1 levels had shorter OS and
DFS than those with low MACC1.
Conclusions: MACC1 may identify low- and high-risk individuals with HCC and be a valuable indicator for
stratifying the prognosis of TNM stage I patients. MACC1 may serve as a novel biomarker for HCC.
Keywords: MACC1, c-MET, hepatocellular carcinoma, prognosis
Background
Hepatocellular carcinoma (HCC) is one of the most
common solid tumours and prevalent fatal cancers
worldwide, especially in East Asia and Sub-Saharan
Africa [1,2]. Recently, HCC mortality rate has increased
faster than the mortality rates for any other leading can-
cers in the United States [3,4]. Surgical resection or liver
transplantation offers the chance of a cure, but only 30-
40% of HCC patients are eligible for curative treatments,
even in developed countries [5]. The HCC recurrence
rate is as high as 54% at 5 years, even in early-stage
HCC after radical resection [6,7]. Survival may vary
widely among HCC patients with the same clinicopatho-
logic features, which is most likely attributable to the
heterogeneity of the biological behaviour of tumour cells
[8,9]. Although recent studies have unravelled some
aberrantly expressed genes contributing to different
prognoses in HCC, the molecular markers that help to
predict early recurrence and serve as potential targets
remain limited.
The importance of understanding the molecular biol-
ogy of HCC has recently gained considerable attention,
as molecular targeting therapy has shown encouraging
results for many malignancies [10,11]. The key signal
transduction pathways implicated in the pathogenesis of
liver cancer include the PI3K/Akt/mTOR pathway [12],
Wnt/b-catenin signalling cascade [13], and HGF/c-MET
pathway [14]. Recently, numerous disorders related to
deregulation of the HGF/c-MET axis have been reported
[15,16]. Aberrant activity of c-MET elicits multiple cel-
lular responses regulating cell morphogenesis, migration,
and breakdown of the extracellular matrix. Dysregula-
tion of c-MET is common in HCC [17], although the
exact mechanisms of this pathway in the carcinogenesis
of HCC are still under investigation. As compounds that
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treatments for c-MET-triggered malignancies may be
designed and the sensitivity of molecular-targeted drugs
that are in clinical use may be improved [18,19].
Poor prognosis of HCC is often associated with a high
potential of vascular invasion and metastasis [20,21]. c-
MET is one of the key players in the processes of disso-
ciation, angiogenesis, and migration of tumour cells in
HCC [17]. Metastasis-associated in colon cancer-1
(MACC1), a new gene associated with colon cancer in
primary and metastatic carcinomas, promotes tumour
cell growth as well as the development of distant metas-
tases [22]. Overexpression of MACC1 induces down-
stream activation of HGF/c-MET and facilitates
metastasis of colon cancer, while silencing of MACC1
leads to reduced tumour proliferation, decreased cell
migration, and a lack of new metastases, indicating the
importance of MACC1 in the phases of cancer progres-
sion. Although MACC1 has been studied in colon carci-
noma, little is known about its role in HCC. To address
this issue, we evaluated the expression of MACC1
mRNA to determine whether MACC1 expression is of
prognostic significance in HCC. Given the tight correla-
tion between MACC1 and c-MET in colon cancer, we
also examined the expression level of c-MET mRNA to
determine whether such correlation exists in HCC.
Methods
Cell lines
Four human HCC cell lines, specifically HepG2, SMMC-
7721, MHCC-97H, and MHCC-97L, and one immorta-
lised nontumourigenic normal human hepatocyte cell
line, L-02, were used to screen the expression of
MACC1. The hepatoma cell line HepG2 was purchased
from the American Type Culture Collection (Manassas,
VA). L-02, SMMC-7721, MHCC-97H and MHCC-97L
were obtained from the Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China) and
maintained under recommended culture conditions.
Cells were grown at 37°C in a humidified incubator con-
taining 5% CO2. RNA was extracted from exponentially
growing cells.
Study population and sample collection
A total of 128 pairs of HCC tissues and adjacent nontu-
morous liver tissues were obtained from patients who
underwent hepatectomy consecutively in a single group
at the Department of Hepatobiliary Surgery, Sun Yat-
sen Cancer Center, between January 2001 and Decem-
ber 2006 and who fulfilled the following criteria: (1)
exclusive treatment with chemotherapy or radiotherapy
before tumour excision, (2) no evidence of concomitant
extrahepatic disease, (3) no simultaneous use of local
treatment modalities (i.e., radiofrequency ablation,
microwave ablation). The patients included 116 males
(90.6%) and 12 females (9.4%), with a median age of 50
years (range 23-79 years). Tumour size ranged from 1.2
to 19.0 cm, with a median of 6.0 cm. All tumours were
histologically diagnosed as HCC with Edmondson-Stei-
ner grade I in 8 cases, grade II in 61, grade III in 54,
and grade IV in 5. The tumour stages were classified
according to the 6th Edition tumour-node-metastasis
(TNM) classification of the International Union Against
Cancer [23]. Sixty-seven cases were classified as stage I,
26 as stage II, and 35 as stage III. In this study, non-
tumorous tissues adjacent to tumour (NT) were defined
as 2.0 cm from the margin, which were confirmed nega-
tive by histological examination, as used in other studies
[24,25]. Twenty normal non-cirrhotic liver tissue sam-
ples (N), which were from patients with liver haeman-
gioma or focal nodular hyperplasia, were included as
controls. All specimens were obtained immediately after
surgical resection, snap-frozen in liquid nitrogen, and
kept at -80°C until use. All recruited patients provided
written informed consent before hepatectomy, and the
study protocol was approved by the Ethics Committee
of Sun Yat-sen University Cancer Center.
Reverse-transcription PCR analysis
All samples were evaluated in a blinded reverse-tran-
scription polymerase chain reaction (RT-PCR) proce-
dure without knowledge of the clinicopathological or
follow-up data until the PCR results were finalised. PCR
was performed as described previously [26]. Briefly, total
RNA was isolated with TRIzol-A
+ agent and treated
with DNase I (Invitrogen Inc., Carlsbad, CA) to remove
DNA contamination. Reverse transcription was per-
formed with the SuperScript RT kit (Promega Inc.,
Madison, WI) following the manufacturer’s instructions.
The cDNA templates were subjected to PCR amplifica-
tion. The reaction conditions for MACC1 were as fol-
lows: pre-denaturation at 94° for 5 min; 34 cycles of
denaturation at 94° for 30 s, annealing at 60° for 30 s
and extension at 72° for 30 s; and final extension at 72°
for 10 min. The final products were analysed by 2.0%
agarose gel electrophoresis and stained with ethidium
bromide. To detect any potential genomic DNA con-
tamination, PCR reactions were also performed in RNA
control samples that lacked reverse transcriptase during
cDNA synthesis. Each PCR was performed in duplicate.
Real-time quantitative PCR analysis
Real-time quantitative PCR (Q-PCR) was performed in
the same batch of cDNA prepared for RT-PCR to quan-
tify MACC1 mRNA. Moreover, to explore the correla-
tion of MACC1 and c-MET, c-MET mRNA was also
quantified in 128 paired tumour specimens. The primer
sets were 5’-TTCTTTTGATTCCTCCGGTGA-3’
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(reverse) for MACC1;5 ’-GGATGCGTGCATTTAT-
CAGA-3’ (forward) and 5’-GTTGATAGGGCA-
GACGTTCG-3’ (reverse) for 18s rRNA; and 5’-
GCTAAAATGCTGGCACCCTAA-3’ (forward) and 5’-
ATAGTGCTCCCCAATGAAAGTAGAGA-3’ (reverse)
for c-Met. Q-PCR was performed with an ABI Prism
7900 HT Sequence Detection System (Applied Biosys-
tems) and SYBR green I Master Mix kit (Invitrogen).
18s rRNA was analysed to normalise Q-PCR data. The
threshold cycle (Ct) value for triplicate reactions was
averaged, and the relative genomic expression was cal-
culated by 2
-ΔΔCt value [ΔCt = Ct (MACC1) - Ct (18s)]
[27]. Melting curves were performed to ensure only a
single product was amplified.
Follow-up
The follow-up duration was defined as the interval
between the date of operation and the date of death or
last follow-up. The study was censored on 31 January
2010. The median follow-up time was 30.5 months, ran-
ging from 3 to 85 months. All patients were followed up
every 1-3 months in the first year and every 3-6 months
thereafter. The follow-up protocol included physical
examination, serum alpha-fetoprotein (AFP) level, chest
X-ray, and abdominal ultrasonography. Computed
tomography and/or magnetic resonance imaging and/or
positron emission tomography were performed when
intrahepatic relapse or distant metastasis was suspected.
During the course of follow - u p ,6 4o f1 2 8p a t i e n t s
(50.0%) were found with intrahepatic recurrence, 18
patients (14.1%) developed distant metastases, 49
patients (38.3%) died of cancer-related causes, and 79
patients (61.7%) were still alive.
Statistical analysis
All statistical analyses were carried out using the SPSS
16.0 statistical software package (SPSS Inc., Chicago, IL).
T h ec h i - s q u a r et e s to rF i s h e r ’se x a c tt e s tw a su s e dt o
comparison of frequencies. Spearman’s correlation test
was applied to analyse the correlation. Overall and dis-
ease-free survival curves were generated using the
Kaplan-Meier method, and t h ed i f f e r e n c eb e t w e e n
curves was assessed by the log-rank test. Independent
prognostic factors were estimated by the Cox propor-
tional hazards stepwise regression model. All P values
were 2-sided. A P value of less than 0.05 was considered
statistically significant.
Results
MACC1 expression in human hepatoma cell lines and HCC
tissues
We first examined MACC1 expression in five liver cell
lines. RT-PCR showed that there was a lack of MACC1
expression in the normal liver cell line L-02, while all of
four hepatoma cell lines (SMMC-7721, Hep-G2,
MHCC-97L and MHCC-97H) expressed MACC1
mRNA (Figure 1A). Of 128 paired HCC patients’ speci-
mens, the frequency of MACC1-positive expression was
significantly higher in HCC tissues (53/128, 41.4%) than
in the corresponding non-tumorous liver tissues (27/
128, 21.1%, P < 0.001). The expression of MACC1
mRNA in normal non-cirrhotic liver tissues was unde-
tectable (Figure 1B).
Similar results were obtained from the same batch of
cell lines using Q-PCR, which indicated high MACC1
mRNA expression in liver cancer cell lines, while there
was low expression in normal liver cells (Figure 1C). In
128 paired HCC patients’ specimens, Q-PCR showed
that MACC1 mRNA expression was higher in HCC tis-
sues than in adjacent non-tumorous liver tissues or nor-
mal tissues (P =0 . 0 0 9 ,P = 0.008, respectively) (Figure
1D). The dissociation curve showed a single peak as
expected for MACC1 (data not shown). As we expected,
Spearman’s correlation test showed that the high-level
expression of MACC1 detected by Q-PCR always indi-
cated positive expression MACC1 according to RT-PCR
(r = 0.223, P = 0.011).
Correlation between MACC1 and c-MET mRNA expression
To address whether MACC1 and c-MET mRNA levels
were correlated, Q-PCR was applied to compare them
in 128 paired HCC specimens. When the expression
levels of both MACC1 and c-MET were plotted on a
scatterplot diagram, the positive relationship became
clear (Figure 2A). There was indeed a significant positive
correlation between the expression levels of MACC1
and c-MET (r = 0.235, P = 0.009, Spearman’sc o r r e l a -
tion test). In addition, the expression level of c-MET
was significantly higher in HCC tissues compared with
adjacent non-cancerous tissues (P < 0.001) (Figure 2B).
Correlation of MACC1 mRNA expression and
clinicopathologic parameters
Next, to explore potential cutoff values for MACC1,a
threshold value was chosen using a minimum P value
approach as described by Mazumdar et al. [28]. In the
multivariable setting, the level of MACC1 in HCC tissue
that was associated with survival in terms of the mini-
mum P value was 2.3-fold that of the non-cancerous tis-
sue level. In the present study, 51 patients with 2.3-fold
or more increased MACC1 in HCC tissues were defined
as high-level, and 77 cases with below 2.3-fold expres-
sion were consider low-level. It should be mentioned
that among 128 patients, 5 patients labelled as positive
with conventional PCR were classified into the low
group, while 3 MACC1-negative patients belonged to
the high group. The slight inconsistency between Q-
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Page 3 of 10Figure 1 Analysis of MACC1 expression in liver tissues and cell lines. A: MACC1 expression in four human hepatoma cell lines (HepG2,
SMMC-7721, MHCC-97H, and MHCC-97L) and one normal liver cell line, L-02, by reverse-transcription PCR (RT-PCR). B: Representative MACC1
mRNA expression in hepatocellular carcinomas (T) and matching non-cancerous (NT) and normal non-cirrhosis (N) liver tissue using RT-PCR. An
RT-negative control (-) was added to rule out false positives resulting from contaminated DNA. Products of 136 bp were expected for MACC1
transcripts. C: Comparison of MACC1 expression levels in five liver cell lines, as determined by real-time quantitative-PCR (Q-PCR). D: Comparison
of MACC1 expression levels in 20 normal liver tissues (N), and 128 paired HCC with matching non-cancerous (NT) specimens by Q-PCR. The
differences among HCC tissues (median 1.632), the adjacent non-cancerous tissues (median 0.601), and normal tissues (median 0.218) are
significant (P = 0.009, P = 0.008, respectively), and no significant difference was found between the adjacent non-cancerous and normal tissues
(P = 0.136).
Figure 2 c-MET expression and correlation with MACC1 in 128 paired HCC specimens: A MACC1 levels from 128 HCC specimens were
plotted against c-MET levels from the same patients. Linear regression analysis showed a significant positive correlation between MACC1
and c-MET (r = 0.567, P = 0.001). B Comparison of c-MET expression levels in 128 HCC specimens. The difference between HCC tissues and the
adjacent non-cancerous tissues (NT) is significant (P < 0.001).
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occurred because conventional PCR analysis is more
inclined to be influenced by PCR reaction conditions.
MACC1 mRNA expression was significantly associated
with preoperative serum AFP level using Q-PCR analysis.
High MACC1 expression was more frequent in high-AFP
HCC patients (P = 0.025). No relationship was found
between the expression of MACC1 and other clinico-
pathological variables, including gender, age, hepatitis B
surface antigen (HBsAg) status, liver cirrhosis, TNM
stage, tumour size, tumour number, tumour capsule, vas-
cular invasion, and Edmondson-Steiner grade (Table 1).
Prognostic of HCC subtypes defined by MACC1 level
Significant OS and DFS advantages were observed for
the patients with low MACC1 mRNA. The 5-year OS
rate of the low-level group was 61.9%, which was signifi-
cantly higher than that of the high-level group (37.6%, P
= 0.003). The 5-year DFS rate of the low-level group
was 54.5%, which was significantly higher than that of
the high-level group (33.5%, P = 0.008) (Figure 3). The
associations of OS and DFS with clinicopathological
variables in our 128 cases of HCC are shown in Table 2.
In a multivariate analysis model, MACC1 remained sig-
nificantly associated with OS (HR 2.230; 95% CI, 1.257-
3.957; P = 0.006) and DFS (HR 1.687; 95% CI, 1.034-
2.751; P = 0.036) (Table 3). Low MACC1 indicates
longer distant metastasis-free survival (MFS) for colon
cancer patients[22]. However, no such correlation was
found between MACC1 expression and MFS among
these HCC patients (P = 0.803).
Stratified univariate and multivariate analysis
Because survival might be associated with the pathologi-
cal TNM stage, we stratified the data according to TNM
stage and investigated the prognostic value of MACC1
in different stages. For the 67 TNM stage I patients, sig-
nificant correlations were found between MACC1
expression and OS (P = 0.021) and DFS (P =0 . 0 1 7 )
(Figure 4). MACC1 had no prognostic value regarding
OS or DFS for patients with TNM stage II or III (all P
> 0.05). The associations of OS and DFS with clinico-
pathological features in TNM stage I HCC are shown in
Table 4. In the Cox model adjusting for other prognos-
tic variables, MACC1 was an independent negative prog-
nostic factor for survival in TNM stage I patients (Table
5). Patients with high MACC1 expression had poorer
OS (HR 2.643; 95% CI, 1.103-6.329; P = 0.029) and DFS
(HR 3.316; 95% CI, 1.012-10.859; P = 0.048) than those
with low MACC1 expression in TNM stage I.
Discussion
The transcript levels of MACC1 in normal liver tissue
are 14 × 10
6, as detected by expressed sequence tags
(ESTs), compared with 20 × 10
6 in malignant liver tis-
sue, according to the EST profile viewer of the NCBI
UniGene database http://www.ncbi.nlm.gov/UniGene.
T h e s ew e r es u p p o r t e db yo u r study and another paper
published recently. Shirahata et al. [29] showed that
MACC1 expression was significantly correlated with vas-
cular invasion and serum AFP level. However, with their
Table 1 Correlations between MACC1 mRNA expression
and clinicopathologic features of HCC
Characteristics No.
patients
MACC1 mRNA high
level
P
value*
Gender
Female 12 58.3% (7/12) 0.169
Male 116 37.9% (44/116)
Age (years)
†
≤ 50 65 44.6% (29/65) 0.263
> 50 63 34.9% (22/63)
HBsAg status
Negative 18 33.3% (6/18) 0.543
Positive 110 40.9% (45/110)
AFP (μg/l)
≤ 400 78 32.1% (25/78) 0.025
> 400 50 52.0% (26/50)
Cirrhosis
No 13 30.8% (4/13) 0.481
Yes 115 40.9% (47/115)
Child-Pugh classification
‡
A 116 39.7% (46/116) 0.892
B 12 41.7% (5/12)
Tumour size (cm)
≤ 5 50 40.0% (20/50) 0.977
> 5 78 39.7% (31/78)
Multiple tumours
No 91 39.6% (36/91) 0.918
Yes 37 40.5% (15/37)
Tumour capsule
Complete 32 34.4% (11/32) 0.466
No/
incomplete
96 41.7% (40/96)
Vascular invasion
No 98 37.8% (37/98) 0.383
Yes 30 46.7% (14/30)
Edmondson-Steiner grade
I/II 69 34.8% (24/69) 0.206
III/IV 59 39.8% (27/59)
TNM stage
I 67 31.3% (21/67) 0.077
II 26 42.3% (11/26)
III 35 54.3%(19/31)
MACC1, metastasis-associated in colon cancer-1; HCC, hepatocellular
carcinoma; AFP, a-fetoprotein; HBsAg, hepatitis B surface antigen.
*Chi-square or Fisher’s exact test.
†Patients were divided according to the median age.
‡No patients with Child-Pugh C were included.
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Page 5 of 10Figure 3 Kaplan-Meier survival curves according to MACC1 expression in 128 HCC patients: A Overall survival (log-rank P = 0.003). B
Disease-free survival (log-rank P = 0.008).
Table 2 Univariate prognostic analysis of overall survival and disease-free survival in HCC patients
Variable Overall survival rate (%) Disease-free survival rate (%)
3y 5y P value 3 y 5 y P value
Gender
Female (n = 12) 91.3 61.8 0.328 66.7 66.7 0.176
Male (n = 116) 61.9 51.0 43.8 43.8
Age (years)
≤ 50 (n = 65) 62.5 52.2 0.567 42.7 42.7 0.101
>5 0( n = 63) 67.0 51.9 49.4 49.4
HBsAg status
Negative (n = 18) 88.5 62.1 0.122 71.8 71.8 0.027
Positive (n = 110) 60.5 49.7 41.9 41.9
AFP (μg/l)
≤ 400 (n = 78) 59.3 47.7 0.219 44.3 44.3 0.555
> 400 (n = 50) 75.0 59.8 50.9 50.9
Cirrhosis
No (n = 13) 91.7 80.2 0.053 54.9 54.9 0.184
Yes (n = 115) 61.3 48.1 44.6 44.6
Child-Pugh classification
A( n = 116) 65.4 55.0 0.378 48.8 48.8 0.154
B( n = 12) 58.3 29.2 20.8 20.8
Tumour size (cm)
≤ 5( n = 50) 81.7 77.3 < 0.001 72.1 72.1 < 0.001
>5( n = 78) 52.6 36.3 29.2 29.2
Multiple tumours
No (n = 91) 70.0 60.4 0.002 56.5 56.5 < 0.001
Yes (n = 37) 49.3 30.2 19.8 19.8
Tumour capsule
Complete (n = 32) 71.2 71.2 0.165 61.1 61.1 0.096
No/incomplete (n = 96) 62.5 46.4 41.0 41.0
Vascular invasion
No (n = 98) 71.7 65.3 < 0.001 54.2 54.2 < 0.001
Yes (n = 30) 40.8 11.6 19.4 19.4
TNM stage
I( n = 67) 79.3 72.1 < 0.001 64.7 64.7 < 0.001
II (n = 30) 54.9 38.4 30.8 30.8
III (n = 31) 42.0 22.5 20.7 20.7
Edmondson-Steiner grade
I/II (n = 69) 75.9 63.0 0.004 56.7 56.7 0.003
III/IV (n = 59) 50.6 38.4 33.4 33.4
MACC1 expression level
Low (n = 71) 73.5 61.9 0.003 54.5 54.5 0.008
High (n = 57) 51.8 37.6 33.5 33.5
MACC1, metastasis-associated in colon cancer-1; HCC, hepatocellular carcinoma; AFP, a-fetoprotein; HBsAg, hepatitis B surface antigen.
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power was limited, and the authors did not explore its
clinical predictive value for HCC patients. In this study,
we analysed the mRNA expression of MACC1 in a rela-
tively large population of HCC patients and correlated it
with clinicopathological features and prognosis to deter-
mine whether this biomarker could predict disease out-
comes. MACC1 expression in HCC tissue was
significantly higher than in nonmalignant tissue. Impor-
tantly, high MACC1 expression was significantly corre-
lated with more aggressive behaviour in terms of shorter
OS and DFS and higher serum AFP, which is a putative
clinicopathologic marker of HCC invasiveness and unfa-
vourable prognosis [30]. These data indicate that high
MACC1 expression occurs in HCC and is associated
with an aggressive invasion phenotype. Although ele-
vated MACC1 expression was associated with high AFP
in our study, which agrees with the data of Shirahata et
al., no significant correlation has been observed between
vascular invasion and MACC1 expression. This disparity
presumably stems from different sample sizes and het-
erogeneity of study populations, which led to the rela-
tively low proportion (4/30) of vascular invasion in the
study of Shirahat’s group [29]. Stein et al. observed that
high MACC1 levels indicated poor MFS for colon can-
cer. In contrast to colon cancer, intrahepatic metastasis
is the most frequent pattern in the progression of HCC
[5,31], which may partially explain why no such rela-
tionship was found in this study. However, it is difficult
to define whether intrahepatic recurrence after hepatect-
omy originates from either residual intrahepatic metas-
tasis or metachronous multicentric carcinogenesis
[32,33]. Because the number of extrahepatic metastasis
cases was limited in this study (n = 18), future studies
are needed to address this issue more definitively.
Because MACC1 may promote cell migration and
invasion by upregulating the downstream c-MET gene
in colon cancer [22], we sought to determine whether
such a mechanism might contribute to the increased
invasiveness of HCC induced by MACC1. This study
found a positive association between MACC1 and c-
MET mRNA levels in HCC. This might support the
existence of a regulatory and functional relationship
between MACC1 and c-MET [34,35]. Furthermore,
based on c-MET contributes to the aggressiveness of
HCC [17], this correlation might further indicate that
MACC1 enhances the invasiveness of liver cancer cells.
Our study shows that MACC1 was expressed highly in
HCC samples and cultured cancer cell lines. The
mechanism of this high expression is still unclear, but it
is interesting to note that chromosome region 7p21,
which contains the MACC1 gene [36], frequently
Table 3 Multivariate analysis of factors contributing to overall survival and disease-free survival in HCC patients
Variable Overall survival Disease-free survival
HR (95% CI) P value HR (95% CI) P value
Tumour size 3.008 (1.315-6.881) 0.009 3.227 (1.664-6.260) 0.001
Multiple tumours 1.361 (0.614-3.017) 0.447 2.254 (1.175-4.326) 0.014
Vascular invasion 2.280 (1.140-4.561) 0.020 1.873 (1.002-3.545) 0.049
HBsAg status - - 2.922 (1.153-7.403) 0.024
Edmondson-Steiner grade 1.853 (1.016-3.379) 0.044 1.615 (0.964-2.705) 0.068
TNM stage 1.136 (0.650-1.985) 0.654 0.865 (0.546-1.369) 0.535
MACC1 expression level 2.230 (1.257-3.957) 0.006 1.687 (1.034-2.751) 0.036
MACC1, metastasis-associated in colon cancer-1; HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HR, hazard ratio; CI, confidence interval.
Figure 4 Kaplan-Meier curves according to MACC1 expression in TNM stage I HCC patients: A Overall survival (log-rank P = 0.021), B
Disease-free survival (log-rank P = 0.017).
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Page 7 of 10exhibits aberrant amplification of expression in HCC
[37-39].
We hypothesised that high expression of MACC1 was
causally associated with HCC invasion, based on several
lines of evidence. First, we have shown that high
MACC1 expression in human HCC was associated with
higher serum AFP and shorter OS and DFS. Second, the
level of MACC1 mRNA was high in MHCC-97H cells
(Figure 1C), which are derived from the high-metastasis-
potential cell line MHCC97 [40]. Third, the level of
MACC1 was positively correlated with that of c-MET,
which plays critical roles in cancer cell migration and
metastasis. Because this study enrolled mostly hepatitis
B virus-dependent HCC patients (85.9%), it remains to
be studied whether MACC1 as a marker of aggressive
phenotype can be extended to HCC cases resulting from
other aetiologies. Hepatitis virus-dependent and alcohol-
dependent HCC display overexpression of MYC,
whereas nonalcoholic steatohepatitis may evolve into
malignancy via a MYC-independent mechanism, indicat-
ing that the existence of genetic discrepancies may
occur via different aetiological routes [41]. Whether
MACC1 is associated with certain aetiological factors
needs to be further investigated.
Table 4 Univariate prognostic analysis of overall survival and disease-free survival in TNM stage I HCC patients
Variables Overall survival rate (%) Disease-free survival rate (%)
3y 5y P value 3 y 5 y P value
Gender
Female (n = 9) 100.0 81.8 0.438 77.8 77.8 0.473
Male (n = 58) 75.7 71.1 62.3 62.3
Age (years)
≤ 50 (n = 32) 87.4 80.4 0.213 71.3 71.3 0.560
>5 0( n = 35) 73.0 65.7 59.4 59.4
HBsAg status
Negative (n = 13) 83.9 83.9 0.752 76.2 76.2 0.426
Positive (n = 54 78.2 69.4 62.1 62.1
AFP (μg/l)
≤ 400 (n = 43) 71.0 65.3 0.199 62.1 62.1 0.690
> 400 (n = 24) 91.1 82.8 68.0 68.0
Cirrhosis
No (n = 8) 100.0 100.0 0.128 75.0 75.0 0.565
Yes (n = 59) 76.0 67.5 63.2 63.2
Child-Pugh classification
A( n = 61) 78.9 75.5 0.499 67.2 67.2 0.519
B( n = 6) 83.3 55.6 44.4 44.4
Tumour size (cm)
≤ 5( n = 40) 82.6 82.6 0.061 77.7 77.7 0.006
>5( n = 27) 73.0 57.0 45.7 45.7
Tumour capsule
Complete (n = 26) 81.0 81.0 0.787 67.3 67.3 0.957
No/incomplete (n = 41) 79.1 68.3 63.3 63.3
Edmondson-Steiner grade
I/II (n = 46) 80.9 80.9 0.172 68.3 68.3 0.338
III/IV (n = 21) 73.7 60.0 57.1 57.1
MACC1 expression level
Low (n = 37) 85.6 85.6 0.021 76.5 76.5 0.017
High (n = 30) 71.1 53.3 49.4 49.4
MACC1, metastasis-associated in colon cancer-1; HCC, hepatocellular carcinoma; AFP, a-fetoprotein; HBsAg, hepatitis B surface antigen.
Table 5 Multivariate analysis of factors contributing to
overall survival and disease-free survival in TNM stage I
HCC patients
Variable Overall survival Disease-free survival
HR (95% CI) P
value
HR (95% CI) P
value
Tumour size 3.062(1.280-
7.323)
0.012 2.445(0.794-
7.532)
0.119
MACC1 expression
level
2.643(1.103-
6.329)
0.029 3.316(1.012-
10.859)
0.048
MACC1, metastasis-associated in colon cancer-1; HCC, hepatocellular
carcinoma; HR, hazard ratio; CI, confidence interval.
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Page 8 of 10Clinical stage is the most important factor influencing
the prognosis of HCC patients. Several systems are
available to classify HCC. Among them, the Interna-
tional Union Against Cancer’sT N Ms t a g i n gi so n eo f
the most prevalent. Although the TNM system has suc-
cessfully graded patients on their prognosis according to
clinicopathological variables, it has reached its limit in
providing critical information that may influence treat-
ment strategy. It is difficult for liver surgeons to predict
exactly which individuals will experience relapse among
early-stage patients who have undergone curative treat-
ment. To overcome the limitations of these traditional
systems, many molecular markers have been investigated
and shown to have potential predictive significance.
However, to date, biomarkerst h a tc o u l ds t r a t i f yH C C
patients with curative excision in TNM stage I are still
substantially limited. In our stratified analysis, we found
that MACC1 mRNA expression had clear prognostic
value for OS and DFS in TNM stage I patients. These
data imply that MACC1 mRNA might act as a predic-
tive tool to identify patients with TNM stage I at high
risk of recurrence.
MACC1 may act as a key regulator of the HGF/c-
MET pathway, leading to distant metastases in colon
cancer [22]. The relationships of MACC1 with other sig-
nalling molecules and pathways must be further evalu-
ated to better understand the molecular pathogenesis of
these tumours and develop more effective targeted ther-
apeutic strategies.
Conclusion
This study established a correlation between MACC1
expression and HCC prognosis. MACC1 was highly
expressed in HCC tissues and predicted the prognosis of
HCC patients, suggesting MACC1 may be involved in
the HCC malignant process. This information can be
used to identify high-risk HCC patients who may benefit
from more intensive treatment and follow-up care after
resection of primary tumours. It also justifies further
studies to gain insight into the underlying biology of
M A C C 1a n dt os t r i v ef o rap o s i t i v er e s p o n s ea f t e r
administration of innovative therapies targeted at
MACC1.
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